Robert Stefanovich Sells 2,743 Shares of CryoPort (NASDAQ:CYRX) Stock

CryoPort, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich sold 2,743 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $21,944.00. Following the transaction, the chief financial officer owned 280,371 shares in the company, valued at $2,242,968. This represents a 0.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Robert Stefanovich also recently made the following trade(s):

• On Thursday, March 12th, Robert Stefanovich sold 38,700 shares of CryoPort stock. The shares were sold at an average price of $7.76, for a total value of $300,312.00.

CryoPort Trading Up 4.5%

Shares of CYRX stock opened at $8.36 on Wednesday. CryoPort, Inc. has a 12 month low of $4.63 and a 12 month high of $11.45. The company has a market capitalization of $416.83 million, a P/E ratio of 6.33 and a beta of 1.69. The stock has a 50 day moving average of $9.19 and a two-hundred day moving average of $9.36.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The firm had revenue of $45.45 million for the quarter, compared to the consensus estimate of $42.92 million. CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. Sell-side analysts predict that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

More CryoPort News

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Analyst upgrade/target increase: Needham raised its target to $13 and reiterated a “buy” view, which supports upside expectations and may be helping the stock’s strength. MarketBeat CYRX Analyst Coverage
• Neutral Sentiment: Mixed Q4 results remain in the backdrop — revenue beat consensus but EPS missed modestly; investors may be parsing near-term profitability versus top-line growth. MarketBeat CYRX Earnings Summary
• Neutral Sentiment: Institutional activity: several small/new stakes were reported (various funds adding modest positions); institutional ownership remains high (~93%), which can reduce float volatility but also concentrate moves. MarketBeat CYRX Institutional Ownership
• Negative Sentiment: Insider selling — CEO Jerrell Shelton sold 7,918 shares at an average $8.00 on Mar 16 (ownership decreased ~0.75%), a signal some investors view as negative. CEO SEC Filing
• Negative Sentiment: Significant CFO selling — Robert Stefanovich disclosed a larger sale on Mar 12 of 38,700 shares (~13.15% of his prior holding) and additional sales on Mar 16 (2,743 shares). Large insider liquidation by a senior finance officer can weigh on sentiment. CFO SEC Filing
• Negative Sentiment: Additional insider sales: Mark W. Sawicki sold 3,235 shares and Edward J. Zecchini sold 2,014 shares on Mar 16 — cumulatively these insider dispositions add to negative optics even if dollar amounts are modest. Insider SEC Filings

Institutional Trading of CryoPort

Several institutional investors have recently bought and sold shares of the stock. Corient Private Wealth LLC acquired a new position in CryoPort during the fourth quarter worth $113,000. Invesco Ltd. lifted its holdings in shares of CryoPort by 19.3% during the fourth quarter. Invesco Ltd. now owns 96,541 shares of the company’s stock valued at $927,000 after acquiring an additional 15,607 shares during the period. XTX Topco Ltd acquired a new stake in shares of CryoPort in the 4th quarter valued at $424,000. Tudor Investment Corp ET AL boosted its stake in shares of CryoPort by 3.3% in the 4th quarter. Tudor Investment Corp ET AL now owns 300,414 shares of the company’s stock valued at $2,884,000 after purchasing an additional 9,690 shares in the last quarter. Finally, Quadrature Capital Ltd bought a new stake in shares of CryoPort in the 4th quarter worth about $97,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Needham & Company LLC increased their price objective on shares of CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Wall Street Zen lowered shares of CryoPort from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of CryoPort in a research report on Monday, December 29th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $12.94.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.